FULC Stock Summary and Trading Ideas (Fulcrum Therapeutics | NASDAQ:FULC)

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Fulcrum Therapeutics trades on the NASDAQ stock market under the symbol FULC.

As of January 28, 2026, FULC stock price declined to $10.48 with 432,398 million shares trading.

FULC has a beta of 1.71, meaning it tends to be more sensitive to market movements. FULC has a correlation of 0.10 to the broad based SPY ETF.

FULC has a market cap of $691.37 million. This is considered a Small Cap stock.

In the last 3 years, FULC traded as high as $15.74 and as low as $2.25.

The top ETF exchange traded funds that FULC belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWN.

FULC has outperformed the market in the last year with a price return of +158.8% while the SPY ETF gained +16.2%. FULC has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +4.8% and +1.2%, respectively, while the SPY returned +1.5% and +0.7%, respectively.

FULC support price is $10.36 and resistance is $11.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FULC shares will trade within this expected range on the day.